ALQGC Stock Overview
A biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.072 |
| 52 Week High | €0.16 |
| 52 Week Low | €0.001 |
| Beta | 0.72 |
| 11 Month Change | 0% |
| 3 Month Change | 3.15% |
| 1 Year Change | -28.75% |
| 33 Year Change | -98.36% |
| 5 Year Change | -97.76% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALQGC | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | -0.3% |
| 1Y | -28.8% | -25.5% | -4.2% |
Return vs Industry: ALQGC underperformed the French Biotechs industry which returned -25.5% over the past year.
Return vs Market: ALQGC underperformed the French Market which returned -4.2% over the past year.
Price Volatility
| ALQGC volatility | |
|---|---|
| ALQGC Average Weekly Movement | 89.3% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALQGC's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALQGC's weekly volatility has increased from 46% to 89% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Mathieu Bigois | www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
| ALQGC fundamental statistics | |
|---|---|
| Market cap | €5.03m |
| Earnings (TTM) | -€9.40m |
| Revenue (TTM) | €19.00 |
Over9,999x
P/S Ratio-0.5x
P/E RatioIs ALQGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALQGC income statement (TTM) | |
|---|---|
| Revenue | €19.00 |
| Cost of Revenue | €1.43m |
| Gross Profit | -€1.43m |
| Other Expenses | €7.97m |
| Earnings | -€9.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -7,547,689.47% |
| Net Profit Margin | -49,478,810.53% |
| Debt/Equity Ratio | -133.6% |
How did ALQGC perform over the long term?
See historical performance and comparison